Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
Celgene to launch five new products through to 2020
The company is also trying to extend use of Otezla into additional indications, and despite reporting mixed phase 2 data in ulcerative colitis earlier this year has moved ahead with a
Latest news
-
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
s disease, ulcerative colitis and lupus.
-
Gilead and Galapagos JAK contender scores in RA trial
The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis.
-
Gilead, Galapagos JAK inhibitor clears phase II test
The drug is also in development for rheumatoid arthritis (RA), ulcerative colitis and Crohn’s disease with phase III trials already underway in those indications and results due in the coming ... Like filgotinib, upadacitinib is also being tested in a
-
Immunology keeps Shire figures solid as Takeda takeover nears
There were gains for newer products Entyvio (vedolizumab) or ulcerative colitis, up a third to around $550m, and myeloma therapy Ninlaro (ixazomib) which climbed 43% to $125m, but Takeda is predicting
-
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz
Xeljanz approved in ulcerative colitis. Meanwhile, in its 'innovative health' medicines division, Pfizer has also gained a new approval for Xeljanz. ... A new European Commission approval means the drug is now available as a second line treatment for
More from news
Approximately 19 fully matching, plus 100 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Biosimilars - the same, but different?
The first months of 2015 also saw it approve Remsima and Inflectra for use on the NHS to treat moderately to severely active ulcerative colitis after the failure of conventional therapy.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
Will lead the development of AVX-470 in ulcerative colitis. Former AstraZeneca (AZ) vice president Dr Deborah Hartman has joined Avaxia Biologics as VP research, replacing Dan Tracey who retires. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US. ... The study employs a mixed quantitative/qualitative methodology and is available to purchase alongside our Living with Ulcerative Colitis 2016 5EU report.
-
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report
Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US.
-
Lucid win PMEA Support Agency of the Year 2016
Highly Commended: Excellence in Healthcare Collaboration and Partnerships – The Ulcerative Colitis Endoscopic Index of Severity Online Tool . Jan Steele (Lucid Co-Founder andCOO) commented: “Being recognised for our work at these
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016
Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 ... patients, including both adult and paediatric patients
More from PMHub
Approximately 4 fully matching, plus 7 partially matching documents found.
Featured jobs
- Global Business Development Director – Health Education
-
excellent commission
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Account Director
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Senior Account Manager
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
-
Account Manager / Account Director
-
Competative
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Medical Writer
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
